You are now leaving Mitsubishi Tanabe Pharma Canada and visiting a third-party website.

If you are interested in exploring careers at MTP-CA, please email
contact@mt-pharma-ca.com.

Media Center

Background Image

Press Releases

  • Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (Als) Has Been Added To The Provincial Drug Plan In Manitoba

    TORONTO, ON, December 15, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plans in Prince Edward Island, Newfoundland and Labrador

    Mitsubishi Tanabe Pharma Canada Announces...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plans in New Brunswick and Nova Scotia

    TORONTO, ON, August 29, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Collaboration with the CNDR on First Canadian Real-World Evidence Study of RADICAVA® IV (edaravone) Survival Benefits in ALS

    TORONTO, ON, August 9, 2023 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension (Edaravone)

    TORONTO, ON, July 20, 2023 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Receives Engagement Letter from pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension

    TORONTO, Canada – March 30, 2023 –...

    Read More
  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS

    (MTPA) is pleased to announce a positive...

    Read More
  • Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS

    TORONTO, Canada - May 13, 2022 –...

    Read More
  • MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Nova Scotia has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, July 7, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in New Brunswick

    TORONTO, June 18, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (edaravone) for Amyotrophic Lateral Sclerosis

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • New Country Manager Brings Significant Business Leadership and Healthcare Expertise to Mitsubishi Tanabe Pharma Canada, Inc.

    TORONTO, September 28, 2018 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (Als) Now Eligible For Coverage Through Veteran Affairs Canada And Indigenous Services Canada

    TORONTO, ON, December 13, 2023 –...

    Read More
  • Canadian-Developed AI Technology Aims to Support Early Detection of ALS

    TORONTO, ON, September 20, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in British Columbia

    TORONTO, ON, August 18, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Alberta

    TORONTO, ON, August 3, 2023 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada is Proud to Support a New HCP Directed Program: How to Break the News in ALS/MND

    Mitsubishi Tanabe Pharma Canada is Proud...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces prRADICAVA® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of prRADICAVA® (Edaravone) Oral Suspension for the Treatment of Patients with ALS

    Comprehensive clinical development program...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

    TORONTO, November 23, 2021 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada

    TORONTO, September 21, 2020 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)

    TORONTO, April 22, 2020 - Mitsubishi...

    Read More
  • Update on Canadian Product Availability

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Celebrates Five Years in Canada Supporting and Committed to People Living with ALS

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plans in Saskatchewan

    TORONTO, ON, September 1, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Québec

    TORONTO, ON, August 16, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Ontario

    TORONTO, ON, August 1, 2023 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces New Leadership

    Mitsubishi Tanabe Pharma Canada Announces...

    Read More
  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava® (Edaravone)

    TORONTO, ON August 15, 2022 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program

    TORONTO, March 10, 2021 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia PharmaCare Formulary

    TORONTO, August 19, 2020 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • MTP-CA’s Response to COVID-19

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of RADICAVA™ (Edaravone) to Treat ALS

    TORONTO, October 4, 2018 -- Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (Als) Has Been Added To The Provincial Drug Plan In Manitoba

    TORONTO, ON, December 15, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (Als) Now Eligible For Coverage Through Veteran Affairs Canada And Indigenous Services Canada

    TORONTO, ON, December 13, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Celebrates Five Years in Canada Supporting and Committed to People Living with ALS

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plans in Prince Edward Island, Newfoundland and Labrador

    Mitsubishi Tanabe Pharma Canada Announces...

    Read More
  • Canadian-Developed AI Technology Aims to Support Early Detection of ALS

    TORONTO, ON, September 20, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plans in Saskatchewan

    TORONTO, ON, September 1, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plans in New Brunswick and Nova Scotia

    TORONTO, ON, August 29, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in British Columbia

    TORONTO, ON, August 18, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Québec

    TORONTO, ON, August 16, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Collaboration with the CNDR on First Canadian Real-World Evidence Study of RADICAVA® IV (edaravone) Survival Benefits in ALS

    TORONTO, ON, August 9, 2023 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Alberta

    TORONTO, ON, August 3, 2023 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Ontario

    TORONTO, ON, August 1, 2023 – Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension (Edaravone)

    TORONTO, ON, July 20, 2023 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada is Proud to Support a New HCP Directed Program: How to Break the News in ALS/MND

    Mitsubishi Tanabe Pharma Canada is Proud...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces New Leadership

    Mitsubishi Tanabe Pharma Canada Announces...

    Read More
  • Mitsubishi Tanabe Pharma Canada Receives Engagement Letter from pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension

    TORONTO, Canada – March 30, 2023 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces prRADICAVA® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS

    (MTPA) is pleased to announce a positive...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of prRADICAVA® (Edaravone) Oral Suspension for the Treatment of Patients with ALS

    Comprehensive clinical development program...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava® (Edaravone)

    TORONTO, ON August 15, 2022 – Mitsubishi...

    Read More
  • Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS

    TORONTO, Canada - May 13, 2022 –...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

    TORONTO, November 23, 2021 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program

    TORONTO, March 10, 2021 - Mitsubishi...

    Read More
  • MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada

    TORONTO, September 21, 2020 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia PharmaCare Formulary

    TORONTO, August 19, 2020 - Mitsubishi...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Nova Scotia has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, July 7, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Manitoba has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Saskatchewan has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

    TORONTO, June 30, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces That Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in New Brunswick

    TORONTO, June 18, 2020 - Mitsubishi Tanabe...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Ontario

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)

    TORONTO, April 22, 2020 - Mitsubishi...

    Read More
  • MTP-CA’s Response to COVID-19

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (edaravone) for Amyotrophic Lateral Sclerosis

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Update on Canadian Product Availability

    Mitsubishi Tanabe Pharma Canada (MTP-CA)...

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of RADICAVA™ (Edaravone) to Treat ALS

    TORONTO, October 4, 2018 -- Mitsubishi...

    Read More
  • New Country Manager Brings Significant Business Leadership and Healthcare Expertise to Mitsubishi Tanabe Pharma Canada, Inc.

    TORONTO, September 28, 2018 – Mitsubishi...

    Read More